Holen Sie sich die Stockscreener-App
2.25
3.69%
0.08
Handel nachbörslich:
2.25
Schlusskurs vom Vortag:
$2.17
Offen:
$2.19
24-Stunden-Volumen:
1.18M
Relative Volume:
0.53
Marktkapitalisierung:
$93.56M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-59.69M
KGV:
-1.6187
EPS:
-1.39
Netto-Cashflow:
$-46.54M
1W Leistung:
+19.68%
1M Leistung:
+30.06%
6M Leistung:
+2.27%
1J Leistung:
+65.44%
1-Tages-Spanne:
$2.16
$2.33
1-Wochen-Bereich:
$1.86
$2.33
52-Wochen-Spanne:
$0.6254
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Firmenname
Milestone Pharmaceuticals Inc
Sektor
Branche
Telefon
(514) 336-0444
Adresse
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Vergleichen Sie MIST mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
2.25 | 93.56M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.36 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.75 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.50 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
538.64 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.47 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-06-20 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-25 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-03 | Eingeleitet | Cowen | Outperform |
| 2019-06-03 | Eingeleitet | Jefferies | Buy |
| 2019-06-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Milestone Pharmaceuticals Inc Aktie (MIST) Neueste Nachrichten
Ratios Revealed: Decoding Milestone Pharmaceuticals Inc (MIST)’s Financial Health - DWinneX
Milestone Pharmaceuticals (MIST) Awaits FDA Decision on Cardamyst Resubmission - GuruFocus
Milestone Pharmaceuticals Files Response to FDA for Cardamyst Nasal Spray - MarketScreener
Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha
Milestone Pharmaceuticals Submits Response to FDA for CARDAMYST - TipRanks
Milestone Pharmaceuticals submits response to FDA for PSVT drug - Investing.com
Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting - The Manila Times
Milestone Pharmaceuticals Submits Response To The FDA's CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting - marketscreener.com
Milestone's CARDAMYST Could Become First Self-Administered PSVT Treatment After FDA Response - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded to “Buy” at HC Wainwright - Defense World
Milestone Pharmaceuticals (MIST) Receives Buy Rating from HC Wai - GuruFocus
Milestone Pharmaceuticals (MIST) Receives Buy Rating with $5 Tar - GuruFocus
Milestone Pharmaceuticals (MIST) Receives Buy Rating from HC Wainwright | MIST Stock News - GuruFocus
Northern Trust Corp Purchases 30,772 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals completes US$94.9M initial public offering - McCarthy Tétrault
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Sold by Millennium Management LLC - Defense World
Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - The Manila Times
Milestone Pharmaceuticals Executives Set for Key Presentation at Jefferies Healthcare Conference - Stock Titan
Analysts Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Target Price at $17.00 - Defense World
Milestone Payments: Potential Trouble In The Last Mile? - Life Science Leader
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why - Yahoo Finance
Cubist Systematic Strategies LLC Takes $73,000 Position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Milestone Pharmaceuticals: Q1 Earnings Snapshot - Midland Daily News
Milestone Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Milestone Pharmaceuticals Reports First Quarter 2025 Financial R - GuruFocus
Milestone Pharmaceuticals Navigates Regulatory Challenges and Financial Updates in Q1 2025 - TipRanks
Milestone Pharmaceuticals (MIST) Aims to Resolve FDA Issues for CARDAMYST | MIST Stock News - GuruFocus
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results - marketscreener.com
Milestone Pharmaceuticals reports Q1 EPS (31c) vs (21c) last year - TipRanks
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Milestone's CARDAMYST Gets FDA Path Forward: Manufacturing Issues Only, $56M Cash Runway Revealed - Stock Titan
Milestone Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study - GlobeNewswire
Milestone Pharmaceuticals (MIST) Expected to Announce Earnings on Monday - Defense World
Milestone Pharmaceuticals Inc (MIST) Stock: A Closer Look at the Analyst Ratings - News Heater
Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial - GlobeNewswire
MIST’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
What is Milestone Pharmaceuticals Inc (MIST) Stock Return on Shareholders’ Capital? - Sete News
Deeper Dive: Understanding Milestone Pharmaceuticals Inc (MIST) Through its Various Ratios - DWinneX
Stock Market Recap: Milestone Pharmaceuticals Inc (MIST) Concludes at 0.88, a -60.89 Surge/Decline - DWinneX
The Attractiveness of Investing In Milestone Pharmaceuticals Inc (MIST) is Growing - knoxdaily.com
Milestone Pharmaceuticals Inc (MIST)’s stock price range in the last year - uspostnews.com
Milestone Pharmaceuticals Inc (MIST) looking to reclaim success with recent performance - Sete News
Market Watch Highlights: Milestone Pharmaceuticals Inc (MIST) Ends on an Upturn Note at 1.06 - DWinneX
Milestone Pharmaceuticals Inc’s Mixed Bag: Down -30.82% in 6 Months, Down -48.21% in 30 Days - investchronicle.com
A stock that deserves closer examination: Milestone Pharmaceuticals Inc (MIST) - uspostnews.com
Milestone Pharmaceuticals Inc [MIST] Investment Guide: What You Need to Know - knoxdaily.com
Examining Milestone Pharmaceuticals Inc (MIST) stock is warranted - uspostnews.com
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens - BioSpace
Finanzdaten der Milestone Pharmaceuticals Inc-Aktie (MIST)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.56%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):